Reference

·

Primary source

FDA cannabis medical-grow GAP and GMP licensees 2024

~80-120 operations

As ofFY2024·Sources2·Primary

Active Thai FDA-registered cannabis indoor medical-grow operations under GAP or GMP licensing in 2024. Base case projects ~250-350 by 2027 as recriminalisation of recreational use redirects capex into medical-only facilities.

Figure in context

Active Thai FDA-registered cannabis indoor medical-grow operations under GAP or GMP licensing in 2024. Base case projects ~250-350 by 2027 as recriminalisation of recreational use redirects capex into medical-only facilities.

Active Thai FDA-registered cannabis indoor medical-grow operations under GAP or GMP licensing in 2024. Base case projects ~250-350 by 2027 as recriminalisation of recreational use redirects capex into medical-only facilities.

Time scope

FY2024

Source basis

Primary source

Interpretation notes

What this tells you

Active Thai FDA-registered cannabis indoor medical-grow operations under GAP or GMP licensing in 2024. Base case projects ~250-350 by 2027 as recriminalisation of recreational use redirects capex into medical-only facilities.

What not to do with it

Use the linked report for interpretation and keep basis differences explicit.

Related figures

Adjacent numbers that add context without drowning the value.

Report context

FDA cannabis medical-grow GAP and GMP licensees 2024 · Insight